search
Back to results

Telmisartan Fixed Dose Combination vs Amlodipine in Hypertensive Patients With Type 2 Diabetes Mellitus

Primary Purpose

Hypertension

Status
Completed
Phase
Phase 3
Locations
International
Study Type
Interventional
Intervention
Telmisartan 80
Amlodipine 10
Amlodipine 10
Sponsored by
Boehringer Ingelheim
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Hypertension

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion criteria:

  1. Hypertension defined as a mean in-clinic seated cuff Systolic Blood Pressure >150 mmHg at Visit 3 (Randomisation visit)
  2. Diagnosis of Type 2 diabetes mellitus
  3. =18 years of age at the date of signing the informed consent
  4. Ability to stop current antihypertensive therapy without unacceptable risk to the patient (investigator's discretion)
  5. Ability to provide written informed consent

Exclusion criteria:

  1. Pre-menopausal women (last menstruation <=1 year prior to start of run-in period) who:

    1. are not surgically sterile; and/or
    2. are nursing or pregnant, or
    3. are of child-bearing potential and are NOT practicing acceptable means of birth control or do NOT plan to continue practising an acceptable method throughout the study.

    The only acceptable methods of birth control are:

    • Intrauterine device (IUD);
    • Oral contraceptives (started at least three months prior to start of run-in period)
    • Implantable or injectable contraceptives and
    • Estrogen patch
  2. Night shift workers who routinely sleep during the daytime and whose work hours include midnight to 4:00 a.m.
  3. Known or suspected secondary hypertension (e.g., renal artery stenosis, phaeochromocytoma)
  4. Mean seated Systolic Blood Pressure (SBP) =180 mm Hg and/or mean seated Diastolic Blood Pressure (DBP) =110 mm Hg during any visit of the screening and placebo run-in periods
  5. Patients with Type 1 diabetes mellitus
  6. Renal dysfunction as defined by the following laboratory parameters: Serum creatinine >3.0 mg/dL (or >265 µmol /L) or known creatinine clearance <30 mL/min or clinical markers of severe renal impairment
  7. Bilateral renal artery stenosis, renal artery stenosis in a solitary kidney, post-renal transplant patients or patients with only one kidney
  8. Clinically relevant hypokalaemia or hyperkalaemia
  9. Uncorrected sodium or volume depletion
  10. Primary aldosteronism
  11. Hereditary fructose intolerance
  12. Biliary obstructive disorders (e.g., cholestatis) or hepatic insufficiency
  13. Congestive heart failure New York Heart Academy (NYHA) functional class CHF III-IV (Refer to Appendix 10.3)
  14. Contraindication to a placebo run-in period (e.g., stroke with-in the past six months, myocardial infarction, cardiac surgery, percutaneous transluminal coronary angioplasty, unstable angina or coronary artery bypass graft within the past three months prior to start of run-in period)
  15. Clinically significant ventricular tachycardia, atrial fibrillation, atrial flutter or other clinically relevant cardiac arrhythmias as determined by the Investigator
  16. Hypertrophic obstructive cardiomyopathy, severe obstructive coronary artery disease, aortic stenosis, hemodynamically relevant stenosis of the aortic or mitral valve
  17. Patients whose diabetes has not been stable and controlled for at least the past three months as defined by an HbA1C >10%
  18. Patients who have previously experienced symptoms characteristic of angioedema during treatment with Angiotensin Converting Enzyme (ACE) inhibitors or angiotensin-II receptor antagonists
  19. History of drug or alcohol dependency within six months prior to signing the informed consent form
  20. Concomitant administration of any medications known to affect blood pressure, except medications allowed by the protocol
  21. Any investigational drug therapy within one month of signing the informed consent
  22. Known hypersensitivity to any component of the study drugs (telmisartan, amlodipine, or placebo)
  23. History of non-compliance or inability to comply with prescribed medications or protocol procedures
  24. Any other clinical condition which, in the opinion of the investigator, would not allow safe completion of the protocol and safe administration of telmisartan and amlodipine

Sites / Locations

  • 1235.21.901 Boehringer Ingelheim Investigational Site
  • 1235.21.907 Boehringer Ingelheim Investigational Site
  • 1235.21.913 Boehringer Ingelheim Investigational Site
  • 1235.21.910 Boehringer Ingelheim Investigational Site
  • 1235.21.903 Boehringer Ingelheim Investigational Site
  • 1235.21.905 Boehringer Ingelheim Investigational Site
  • 1235.21.916 Boehringer Ingelheim Investigational Site
  • 1235.21.915 Boehringer Ingelheim Investigational Site
  • 1235.21.906 Boehringer Ingelheim Investigational Site
  • 1235.21.902 Boehringer Ingelheim Investigational Site
  • 1235.21.904 Boehringer Ingelheim Investigational Site
  • 1235.21.908 Boehringer Ingelheim Investigational Site
  • 1235.21.909 Boehringer Ingelheim Investigational Site
  • 1235.21.912 Boehringer Ingelheim Investigational Site
  • 1235.21.911 Boehringer Ingelheim Investigational Site
  • 1235.21.102 Boehringer Ingelheim Investigational Site
  • 1235.21.103 Boehringer Ingelheim Investigational Site
  • 1235.21.107 Boehringer Ingelheim Investigational Site
  • 1235.21.101 Boehringer Ingelheim Investigational Site
  • 1235.21.105 Boehringer Ingelheim Investigational Site
  • 1235.21.202 Boehringer Ingelheim Investigational Site
  • 1235.21.201 Boehringer Ingelheim Investigational Site
  • 1235.21.203 Boehringer Ingelheim Investigational Site
  • 1235.21.204 Boehringer Ingelheim Investigational Site
  • 1235.21.205 Boehringer Ingelheim Investigational Site
  • 1235.21.302 Boehringer Ingelheim Investigational Site
  • 1235.21.304 Boehringer Ingelheim Investigational Site
  • 1235.21.301 Boehringer Ingelheim Investigational Site
  • 1235.21.303 Boehringer Ingelheim Investigational Site
  • 1235.21.305 Boehringer Ingelheim Investigational Site
  • 1235.21.306 Boehringer Ingelheim Investigational Site
  • 1235.21.408 Boehringer Ingelheim Investigational Site
  • 1235.21.406 Boehringer Ingelheim Investigational Site
  • 1235.21.401 Boehringer Ingelheim Investigational Site
  • 1235.21.405 Boehringer Ingelheim Investigational Site
  • 1235.21.404 Boehringer Ingelheim Investigational Site
  • 1235.21.403 Boehringer Ingelheim Investigational Site
  • 1235.21.409 Boehringer Ingelheim Investigational Site
  • 1235.21.407 Boehringer Ingelheim Investigational Site
  • 1235.21.402 Boehringer Ingelheim Investigational Site
  • 1235.21.501 Boehringer Ingelheim Investigational Site
  • 1235.21.502 Boehringer Ingelheim Investigational Site
  • 1235.21.503 Boehringer Ingelheim Investigational Site
  • 1235.21.504 Boehringer Ingelheim Investigational Site
  • 1235.21.507 Boehringer Ingelheim Investigational Site
  • 1235.21.509 Boehringer Ingelheim Investigational Site
  • 1235.21.505 Boehringer Ingelheim Investigational Site
  • 1235.21.506 Boehringer Ingelheim Investigational Site
  • 1235.21.508 Boehringer Ingelheim Investigational Site
  • 1235.21.27005 Boehringer Ingelheim Investigational Site
  • 1235.21.27007 Boehringer Ingelheim Investigational Site
  • 1235.21.27004 Boehringer Ingelheim Investigational Site
  • 1235.21.27006 Boehringer Ingelheim Investigational Site
  • 1235.21.27002 Boehringer Ingelheim Investigational Site
  • 1235.21.27001 Boehringer Ingelheim Investigational Site
  • 1235.21.27003 Boehringer Ingelheim Investigational Site
  • 1235.21.702 Boehringer Ingelheim Investigational Site
  • 1235.21.705 Boehringer Ingelheim Investigational Site
  • 1235.21.703 Boehringer Ingelheim Investigational Site
  • 1235.21.704 Boehringer Ingelheim Investigational Site
  • 1235.21.706 Boehringer Ingelheim Investigational Site
  • 1235.21.801 Boehringer Ingelheim Investigational Site
  • 1235.21.803 Boehringer Ingelheim Investigational Site
  • 1235.21.804 Boehringer Ingelheim Investigational Site
  • 1235.21.802 Boehringer Ingelheim Investigational Site

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Telmisartan 80 / Amlodipine 10

Amlodipine 10

Arm Description

Telmisartan 80 / Amlodipine 5 for two weeks, then forced titration to Telmisartan 80 / Amlodipine 10 Fixed Dose Combination

Amlodipine 5 for two weeks, then forced titration to Amlodipine 10

Outcomes

Primary Outcome Measures

Change From Baseline in Trough Seated Systolic Blood Pressure to Week 8
Trough blood pressure measurements were the measurements observed at the end of the dosing interval just prior to the next dose of medication.

Secondary Outcome Measures

Change From Baseline in Trough Seated Systolic Blood Pressure to Week 6
Trough blood pressure measurements were the measurements observed at the end of the dosing interval just prior to the next dose of medication.
Change From Baseline in Trough Seated Systolic Blood Pressure to Week 4
Trough blood pressure measurements were the measurements observed at the end of the dosing interval just prior to the next dose of medication.
Change From Baseline in Trough Seated Systolic Blood Pressure to Week 2
Trough blood pressure measurements were the measurements observed at the end of the dosing interval just prior to the next dose of medication.
Change From Baseline in Trough Seated Systolic Blood Pressure to Week 1
Trough blood pressure measurements were the measurements observed at the end of the dosing interval just prior to the next dose of medication.
Blood Pressure (BP) Control (SBP<140 mmHg, DBP<90 mmHg) at Eight Weeks
Mean seated SBP<140 mmHg and mean seated DBP<90 mmHg
BP Control (SBP<140 mmHg, DBP<90 mmHg) at Six Weeks
Mean seated SBP<140 mmHg and mean seated DBP<90 mmHg
BP Control (SBP<140 mmHg, DBP<90 mmHg) at Four Weeks
Mean seated SBP<140 mmHg and mean seated DBP<90 mmHg
BP Control (SBP<140 mmHg, DBP<90 mmHg) at Two Weeks
Mean seated SBP<140 mmHg and mean seated DBP<90 mmHg
BP Control (SBP<140 mmHg, DBP<90 mmHg) at One Week
Mean seated SBP<140 mmHg and mean seated DBP<90 mmHg
BP Control (SBP<130 mmHg, DBP<80 mmHg) at Eight Weeks
Mean seated SBP<130 mmHg and mean seated DBP<80 mmHg
BP Control (SBP<130 mmHg, DBP<80 mmHg) at Six Weeks
Mean seated SBP<130 mmHg and mean seated DBP<80 mmHg
BP Control (SBP<130 mmHg, DBP<80 mmHg) at Four Weeks
Mean seated SBP<130 mmHg and mean seated DBP<80 mmHg
BP Control (SBP<130 mmHg, DBP<80 mmHg) at Two Weeks
Mean seated SBP<130 mmHg and mean seated DBP<80 mmHg
BP Control (SBP<130 mmHg, DBP<80 mmHg) at One Week
Mean seated SBP<130 mmHg and mean seated DBP<80 mmHg
Systolic Blood Pressure (SBP) Control 140 at Eight Weeks
Mean seated SBP < 140 mmHg
SBP Control 140 at Six Weeks
Mean seated SBP < 140 mmHg
SBP Control 140 at Four Weeks
Mean seated SBP < 140 mmHg
SBP Control 140 at Two Weeks
Mean seated SBP < 140 mmHg
SBP Control 140 at One Week
Mean seated SBP < 140 mmHg
SBP Control 130 at Eight Weeks
Mean seated SBP < 130 mmHg
SBP Control 130 at Six Weeks
Mean seated SBP < 130 mmHg
SBP Control 130 at Four Weeks
Mean seated SBP < 130 mmHg
SBP Control 130 at Two Weeks
Mean seated SBP < 130 mmHg
SBP Control 130 at One Week
Mean seated SBP < 130 mmHg
SBP Response 140 at Eight Weeks
SBP < 140 mmHg or a reduction >=10 mmHg
SBP Response 140 at Six Weeks
SBP <140 mmHg or a reduction >=10 mmHg
SBP Response 140 at Four Weeks
SBP <140 mmHg or a reduction >=10 mmHg
SBP Response 140 at Two Weeks
SBP <140 mmHg or a reduction >=10 mmHg
SBP Response 140 at One Week
SBP <140 mmHg or a reduction >=10 mmHg
SBP Response 130 at Eight Weeks
SBP <130 mmHg or a reduction >=10 mmHg
SBP Response 130 at Six Weeks
SBP <130 mmHg or a reduction >=10 mmHg
SBP Response 130 at Four Weeks
SBP <130 mmHg or a reduction >=10 mmHg
SBP Response 130 at Two Weeks
SBP <130 mmHg or a reduction >=10 mmHg
SBP Response 130 at One Week
SBP <130 mmHg or a reduction >=10 mmHg
DBP Response at Eight Weeks
Mean seated DBP<80 mmHg or a reduction of <=10 mmHg
DBP Response at Six Weeks
Mean seated DBP<80 mmHg or a reduction of <=10 mmHg
DBP Response at Week Four
Mean seated DBP <80 mmHg or a reduction of >=10 mmHg
DBP Response at Week Two
Mean seated DBP <80 mmHg or a reduction of >=10 mmHg
DBP Response at Week One
Mean seated DBP <80 mmHg or a reduction of >=10 mmHg
Change From Baseline in Urine Albumin:Creatinine Ratio (UACR)
Change from baseline in UACR (measured in spot urine) after eight weeks of treatment

Full Information

First Posted
February 6, 2009
Last Updated
February 10, 2014
Sponsor
Boehringer Ingelheim
search

1. Study Identification

Unique Protocol Identification Number
NCT00877929
Brief Title
Telmisartan Fixed Dose Combination vs Amlodipine in Hypertensive Patients With Type 2 Diabetes Mellitus
Official Title
An 8-week Randomised, Double-blind Study to Compare the Fixed-dose Combination of Telmisartan 80 + Amlodipine 10mg Versus Amlodipine 10 mg Monotherapy as First Line Therapy in Type 2 Diabetes Patients With Hypertension.
Study Type
Interventional

2. Study Status

Record Verification Date
February 2014
Overall Recruitment Status
Completed
Study Start Date
February 2009 (undefined)
Primary Completion Date
May 2010 (Actual)
Study Completion Date
undefined (undefined)

3. Sponsor/Collaborators

Name of the Sponsor
Boehringer Ingelheim

4. Oversight

5. Study Description

Brief Summary
To demonstrate that the fixed dose combination of telmisartan and amlodipine is more effective in lowering blood pressure.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypertension

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
Double
Allocation
Randomized
Enrollment
706 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Telmisartan 80 / Amlodipine 10
Arm Type
Experimental
Arm Description
Telmisartan 80 / Amlodipine 5 for two weeks, then forced titration to Telmisartan 80 / Amlodipine 10 Fixed Dose Combination
Arm Title
Amlodipine 10
Arm Type
Active Comparator
Arm Description
Amlodipine 5 for two weeks, then forced titration to Amlodipine 10
Intervention Type
Drug
Intervention Name(s)
Telmisartan 80
Intervention Description
Telmisartan 80 mg
Intervention Type
Drug
Intervention Name(s)
Amlodipine 10
Intervention Description
Amlodipine 5 for two weeks, then forced titration to Amlodipine 10
Intervention Type
Drug
Intervention Name(s)
Amlodipine 10
Intervention Description
Amlodipine 5 for two weeks, then forced titration to Amlodipine 10
Primary Outcome Measure Information:
Title
Change From Baseline in Trough Seated Systolic Blood Pressure to Week 8
Description
Trough blood pressure measurements were the measurements observed at the end of the dosing interval just prior to the next dose of medication.
Time Frame
Baseline, week 8
Secondary Outcome Measure Information:
Title
Change From Baseline in Trough Seated Systolic Blood Pressure to Week 6
Description
Trough blood pressure measurements were the measurements observed at the end of the dosing interval just prior to the next dose of medication.
Time Frame
Baseline, week 6
Title
Change From Baseline in Trough Seated Systolic Blood Pressure to Week 4
Description
Trough blood pressure measurements were the measurements observed at the end of the dosing interval just prior to the next dose of medication.
Time Frame
Baseline, week 4
Title
Change From Baseline in Trough Seated Systolic Blood Pressure to Week 2
Description
Trough blood pressure measurements were the measurements observed at the end of the dosing interval just prior to the next dose of medication.
Time Frame
Baseline, week 2
Title
Change From Baseline in Trough Seated Systolic Blood Pressure to Week 1
Description
Trough blood pressure measurements were the measurements observed at the end of the dosing interval just prior to the next dose of medication.
Time Frame
Baseline, week 1
Title
Blood Pressure (BP) Control (SBP<140 mmHg, DBP<90 mmHg) at Eight Weeks
Description
Mean seated SBP<140 mmHg and mean seated DBP<90 mmHg
Time Frame
Baseline, week 8
Title
BP Control (SBP<140 mmHg, DBP<90 mmHg) at Six Weeks
Description
Mean seated SBP<140 mmHg and mean seated DBP<90 mmHg
Time Frame
Baseline, week 6
Title
BP Control (SBP<140 mmHg, DBP<90 mmHg) at Four Weeks
Description
Mean seated SBP<140 mmHg and mean seated DBP<90 mmHg
Time Frame
Baseline, week 4
Title
BP Control (SBP<140 mmHg, DBP<90 mmHg) at Two Weeks
Description
Mean seated SBP<140 mmHg and mean seated DBP<90 mmHg
Time Frame
Baseline, week 2
Title
BP Control (SBP<140 mmHg, DBP<90 mmHg) at One Week
Description
Mean seated SBP<140 mmHg and mean seated DBP<90 mmHg
Time Frame
Baseline, week 1
Title
BP Control (SBP<130 mmHg, DBP<80 mmHg) at Eight Weeks
Description
Mean seated SBP<130 mmHg and mean seated DBP<80 mmHg
Time Frame
Baseline, week 8
Title
BP Control (SBP<130 mmHg, DBP<80 mmHg) at Six Weeks
Description
Mean seated SBP<130 mmHg and mean seated DBP<80 mmHg
Time Frame
Baseline, week 6
Title
BP Control (SBP<130 mmHg, DBP<80 mmHg) at Four Weeks
Description
Mean seated SBP<130 mmHg and mean seated DBP<80 mmHg
Time Frame
Baseline, week 4
Title
BP Control (SBP<130 mmHg, DBP<80 mmHg) at Two Weeks
Description
Mean seated SBP<130 mmHg and mean seated DBP<80 mmHg
Time Frame
Baseline, week 2
Title
BP Control (SBP<130 mmHg, DBP<80 mmHg) at One Week
Description
Mean seated SBP<130 mmHg and mean seated DBP<80 mmHg
Time Frame
Baseline, week 1
Title
Systolic Blood Pressure (SBP) Control 140 at Eight Weeks
Description
Mean seated SBP < 140 mmHg
Time Frame
Baseline, week 8
Title
SBP Control 140 at Six Weeks
Description
Mean seated SBP < 140 mmHg
Time Frame
Baseline, week 6
Title
SBP Control 140 at Four Weeks
Description
Mean seated SBP < 140 mmHg
Time Frame
Baseline, week 4
Title
SBP Control 140 at Two Weeks
Description
Mean seated SBP < 140 mmHg
Time Frame
Baseline, week 2
Title
SBP Control 140 at One Week
Description
Mean seated SBP < 140 mmHg
Time Frame
Baseline, week 1
Title
SBP Control 130 at Eight Weeks
Description
Mean seated SBP < 130 mmHg
Time Frame
Baseline, week 8
Title
SBP Control 130 at Six Weeks
Description
Mean seated SBP < 130 mmHg
Time Frame
Baseline, week 6
Title
SBP Control 130 at Four Weeks
Description
Mean seated SBP < 130 mmHg
Time Frame
Baseline, week 4
Title
SBP Control 130 at Two Weeks
Description
Mean seated SBP < 130 mmHg
Time Frame
Baseline, week 2
Title
SBP Control 130 at One Week
Description
Mean seated SBP < 130 mmHg
Time Frame
Baseline, week 1
Title
SBP Response 140 at Eight Weeks
Description
SBP < 140 mmHg or a reduction >=10 mmHg
Time Frame
Baseline, week 8
Title
SBP Response 140 at Six Weeks
Description
SBP <140 mmHg or a reduction >=10 mmHg
Time Frame
Baseline, week 6
Title
SBP Response 140 at Four Weeks
Description
SBP <140 mmHg or a reduction >=10 mmHg
Time Frame
Baseline, week 4
Title
SBP Response 140 at Two Weeks
Description
SBP <140 mmHg or a reduction >=10 mmHg
Time Frame
Baseline, week 2
Title
SBP Response 140 at One Week
Description
SBP <140 mmHg or a reduction >=10 mmHg
Time Frame
Baseline, week 1
Title
SBP Response 130 at Eight Weeks
Description
SBP <130 mmHg or a reduction >=10 mmHg
Time Frame
Baseline, week 8
Title
SBP Response 130 at Six Weeks
Description
SBP <130 mmHg or a reduction >=10 mmHg
Time Frame
Baseline, week 6
Title
SBP Response 130 at Four Weeks
Description
SBP <130 mmHg or a reduction >=10 mmHg
Time Frame
Baseline, week 4
Title
SBP Response 130 at Two Weeks
Description
SBP <130 mmHg or a reduction >=10 mmHg
Time Frame
Baseline, week 2
Title
SBP Response 130 at One Week
Description
SBP <130 mmHg or a reduction >=10 mmHg
Time Frame
Baseline, week 1
Title
DBP Response at Eight Weeks
Description
Mean seated DBP<80 mmHg or a reduction of <=10 mmHg
Time Frame
Week 8
Title
DBP Response at Six Weeks
Description
Mean seated DBP<80 mmHg or a reduction of <=10 mmHg
Time Frame
week 6
Title
DBP Response at Week Four
Description
Mean seated DBP <80 mmHg or a reduction of >=10 mmHg
Time Frame
Week 4
Title
DBP Response at Week Two
Description
Mean seated DBP <80 mmHg or a reduction of >=10 mmHg
Time Frame
Week 2
Title
DBP Response at Week One
Description
Mean seated DBP <80 mmHg or a reduction of >=10 mmHg
Time Frame
Week 1
Title
Change From Baseline in Urine Albumin:Creatinine Ratio (UACR)
Description
Change from baseline in UACR (measured in spot urine) after eight weeks of treatment
Time Frame
8 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion criteria: Hypertension defined as a mean in-clinic seated cuff Systolic Blood Pressure >150 mmHg at Visit 3 (Randomisation visit) Diagnosis of Type 2 diabetes mellitus =18 years of age at the date of signing the informed consent Ability to stop current antihypertensive therapy without unacceptable risk to the patient (investigator's discretion) Ability to provide written informed consent Exclusion criteria: Pre-menopausal women (last menstruation <=1 year prior to start of run-in period) who: are not surgically sterile; and/or are nursing or pregnant, or are of child-bearing potential and are NOT practicing acceptable means of birth control or do NOT plan to continue practising an acceptable method throughout the study. The only acceptable methods of birth control are: Intrauterine device (IUD); Oral contraceptives (started at least three months prior to start of run-in period) Implantable or injectable contraceptives and Estrogen patch Night shift workers who routinely sleep during the daytime and whose work hours include midnight to 4:00 a.m. Known or suspected secondary hypertension (e.g., renal artery stenosis, phaeochromocytoma) Mean seated Systolic Blood Pressure (SBP) =180 mm Hg and/or mean seated Diastolic Blood Pressure (DBP) =110 mm Hg during any visit of the screening and placebo run-in periods Patients with Type 1 diabetes mellitus Renal dysfunction as defined by the following laboratory parameters: Serum creatinine >3.0 mg/dL (or >265 µmol /L) or known creatinine clearance <30 mL/min or clinical markers of severe renal impairment Bilateral renal artery stenosis, renal artery stenosis in a solitary kidney, post-renal transplant patients or patients with only one kidney Clinically relevant hypokalaemia or hyperkalaemia Uncorrected sodium or volume depletion Primary aldosteronism Hereditary fructose intolerance Biliary obstructive disorders (e.g., cholestatis) or hepatic insufficiency Congestive heart failure New York Heart Academy (NYHA) functional class CHF III-IV (Refer to Appendix 10.3) Contraindication to a placebo run-in period (e.g., stroke with-in the past six months, myocardial infarction, cardiac surgery, percutaneous transluminal coronary angioplasty, unstable angina or coronary artery bypass graft within the past three months prior to start of run-in period) Clinically significant ventricular tachycardia, atrial fibrillation, atrial flutter or other clinically relevant cardiac arrhythmias as determined by the Investigator Hypertrophic obstructive cardiomyopathy, severe obstructive coronary artery disease, aortic stenosis, hemodynamically relevant stenosis of the aortic or mitral valve Patients whose diabetes has not been stable and controlled for at least the past three months as defined by an HbA1C >10% Patients who have previously experienced symptoms characteristic of angioedema during treatment with Angiotensin Converting Enzyme (ACE) inhibitors or angiotensin-II receptor antagonists History of drug or alcohol dependency within six months prior to signing the informed consent form Concomitant administration of any medications known to affect blood pressure, except medications allowed by the protocol Any investigational drug therapy within one month of signing the informed consent Known hypersensitivity to any component of the study drugs (telmisartan, amlodipine, or placebo) History of non-compliance or inability to comply with prescribed medications or protocol procedures Any other clinical condition which, in the opinion of the investigator, would not allow safe completion of the protocol and safe administration of telmisartan and amlodipine
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Boehringer Ingelheim
Organizational Affiliation
Boehringer Ingelheim
Official's Role
Study Chair
Facility Information:
Facility Name
1235.21.901 Boehringer Ingelheim Investigational Site
City
Long Beach
State/Province
California
Country
United States
Facility Name
1235.21.907 Boehringer Ingelheim Investigational Site
City
Tustin
State/Province
California
Country
United States
Facility Name
1235.21.913 Boehringer Ingelheim Investigational Site
City
Fort Lauderdale
State/Province
Florida
Country
United States
Facility Name
1235.21.910 Boehringer Ingelheim Investigational Site
City
Hollywood
State/Province
Florida
Country
United States
Facility Name
1235.21.903 Boehringer Ingelheim Investigational Site
City
Pembroke Pines
State/Province
Florida
Country
United States
Facility Name
1235.21.905 Boehringer Ingelheim Investigational Site
City
Tucker
State/Province
Georgia
Country
United States
Facility Name
1235.21.916 Boehringer Ingelheim Investigational Site
City
Olive Branch
State/Province
Mississippi
Country
United States
Facility Name
1235.21.915 Boehringer Ingelheim Investigational Site
City
Hickory
State/Province
North Carolina
Country
United States
Facility Name
1235.21.906 Boehringer Ingelheim Investigational Site
City
Winston-Salem
State/Province
North Carolina
Country
United States
Facility Name
1235.21.902 Boehringer Ingelheim Investigational Site
City
Oklahoma City
State/Province
Oklahoma
Country
United States
Facility Name
1235.21.904 Boehringer Ingelheim Investigational Site
City
Penndel
State/Province
Pennsylvania
Country
United States
Facility Name
1235.21.908 Boehringer Ingelheim Investigational Site
City
Carrollton
State/Province
Texas
Country
United States
Facility Name
1235.21.909 Boehringer Ingelheim Investigational Site
City
Dallas
State/Province
Texas
Country
United States
Facility Name
1235.21.912 Boehringer Ingelheim Investigational Site
City
Killeen
State/Province
Texas
Country
United States
Facility Name
1235.21.911 Boehringer Ingelheim Investigational Site
City
Ettrick
State/Province
Virginia
Country
United States
Facility Name
1235.21.102 Boehringer Ingelheim Investigational Site
City
Capital Federal
Country
Argentina
Facility Name
1235.21.103 Boehringer Ingelheim Investigational Site
City
Capital Federal
Country
Argentina
Facility Name
1235.21.107 Boehringer Ingelheim Investigational Site
City
Ramos Mejía
Country
Argentina
Facility Name
1235.21.101 Boehringer Ingelheim Investigational Site
City
Santa Fe
Country
Argentina
Facility Name
1235.21.105 Boehringer Ingelheim Investigational Site
City
Zárate
Country
Argentina
Facility Name
1235.21.202 Boehringer Ingelheim Investigational Site
City
Incheon
Country
Korea, Republic of
Facility Name
1235.21.201 Boehringer Ingelheim Investigational Site
City
Seoul
Country
Korea, Republic of
Facility Name
1235.21.203 Boehringer Ingelheim Investigational Site
City
Seoul
Country
Korea, Republic of
Facility Name
1235.21.204 Boehringer Ingelheim Investigational Site
City
Seoul
Country
Korea, Republic of
Facility Name
1235.21.205 Boehringer Ingelheim Investigational Site
City
Seoul
Country
Korea, Republic of
Facility Name
1235.21.302 Boehringer Ingelheim Investigational Site
City
Acapulco
Country
Mexico
Facility Name
1235.21.304 Boehringer Ingelheim Investigational Site
City
Aguascalientes
Country
Mexico
Facility Name
1235.21.301 Boehringer Ingelheim Investigational Site
City
Guadalajara
Country
Mexico
Facility Name
1235.21.303 Boehringer Ingelheim Investigational Site
City
Guadalajara
Country
Mexico
Facility Name
1235.21.305 Boehringer Ingelheim Investigational Site
City
Guadalajara
Country
Mexico
Facility Name
1235.21.306 Boehringer Ingelheim Investigational Site
City
Guadalajara
Country
Mexico
Facility Name
1235.21.408 Boehringer Ingelheim Investigational Site
City
Beek en Donk
Country
Netherlands
Facility Name
1235.21.406 Boehringer Ingelheim Investigational Site
City
Den Haag
Country
Netherlands
Facility Name
1235.21.401 Boehringer Ingelheim Investigational Site
City
Hoogwoud
Country
Netherlands
Facility Name
1235.21.405 Boehringer Ingelheim Investigational Site
City
Musselkanaal
Country
Netherlands
Facility Name
1235.21.404 Boehringer Ingelheim Investigational Site
City
Nijverdal
Country
Netherlands
Facility Name
1235.21.403 Boehringer Ingelheim Investigational Site
City
Oude Pekela
Country
Netherlands
Facility Name
1235.21.409 Boehringer Ingelheim Investigational Site
City
Roelofarensveen
Country
Netherlands
Facility Name
1235.21.407 Boehringer Ingelheim Investigational Site
City
Voerendaal
Country
Netherlands
Facility Name
1235.21.402 Boehringer Ingelheim Investigational Site
City
Wildervank
Country
Netherlands
Facility Name
1235.21.501 Boehringer Ingelheim Investigational Site
City
Bratislava
Country
Slovakia
Facility Name
1235.21.502 Boehringer Ingelheim Investigational Site
City
Bratislava
Country
Slovakia
Facility Name
1235.21.503 Boehringer Ingelheim Investigational Site
City
Bratislava
Country
Slovakia
Facility Name
1235.21.504 Boehringer Ingelheim Investigational Site
City
Bratislava
Country
Slovakia
Facility Name
1235.21.507 Boehringer Ingelheim Investigational Site
City
Dunajska Streda
Country
Slovakia
Facility Name
1235.21.509 Boehringer Ingelheim Investigational Site
City
Martin
Country
Slovakia
Facility Name
1235.21.505 Boehringer Ingelheim Investigational Site
City
Nitra
Country
Slovakia
Facility Name
1235.21.506 Boehringer Ingelheim Investigational Site
City
Nitra
Country
Slovakia
Facility Name
1235.21.508 Boehringer Ingelheim Investigational Site
City
Rimavska Sobota
Country
Slovakia
Facility Name
1235.21.27005 Boehringer Ingelheim Investigational Site
City
Cape Town
Country
South Africa
Facility Name
1235.21.27007 Boehringer Ingelheim Investigational Site
City
Cape Town
Country
South Africa
Facility Name
1235.21.27004 Boehringer Ingelheim Investigational Site
City
Durban
Country
South Africa
Facility Name
1235.21.27006 Boehringer Ingelheim Investigational Site
City
Johannesburg
Country
South Africa
Facility Name
1235.21.27002 Boehringer Ingelheim Investigational Site
City
Krugersdorp
Country
South Africa
Facility Name
1235.21.27001 Boehringer Ingelheim Investigational Site
City
Lenasia
Country
South Africa
Facility Name
1235.21.27003 Boehringer Ingelheim Investigational Site
City
Pretoria
Country
South Africa
Facility Name
1235.21.702 Boehringer Ingelheim Investigational Site
City
Castellón
Country
Spain
Facility Name
1235.21.705 Boehringer Ingelheim Investigational Site
City
Centelles
Country
Spain
Facility Name
1235.21.703 Boehringer Ingelheim Investigational Site
City
Sant Adrià del Besós
Country
Spain
Facility Name
1235.21.704 Boehringer Ingelheim Investigational Site
City
Santa Coloma de Gramanet (Barcelona)
Country
Spain
Facility Name
1235.21.706 Boehringer Ingelheim Investigational Site
City
Santa Coloma de Gramanet
Country
Spain
Facility Name
1235.21.801 Boehringer Ingelheim Investigational Site
City
Göteborg
Country
Sweden
Facility Name
1235.21.803 Boehringer Ingelheim Investigational Site
City
Helsingborg
Country
Sweden
Facility Name
1235.21.804 Boehringer Ingelheim Investigational Site
City
Lund
Country
Sweden
Facility Name
1235.21.802 Boehringer Ingelheim Investigational Site
City
Västerås
Country
Sweden

12. IPD Sharing Statement

Links:
URL
http://trials.boehringer-ingelheim.com/content/dam/internet/opu/clinicaltrial/com_EN/results/1235/1235.21_U11-3091.pdf
Description
Related Info
URL
http://trials.boehringer-ingelheim.com/content/dam/internet/opu/clinicaltrial/com_EN/results/1235/1235.21_literature.pdf
Description
Related Info

Learn more about this trial

Telmisartan Fixed Dose Combination vs Amlodipine in Hypertensive Patients With Type 2 Diabetes Mellitus

We'll reach out to this number within 24 hrs